History Of Atrial Fibrillation In A First-Degree Relative

Slides:



Advertisements
Similar presentations
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
Evidence That D-dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Oral Anticoagulant.
Glucose Levels and Risk of Dementia Presented by - Anas Kabaha, MD Sheba medical center Sheba medical center August 8,2013.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.
1 ATRIAL FIBRILLATION AT BASELINE AND DURING FOLLOW-UP in The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial November 9, 2003.
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.
Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events Andres J. Yarur, MD, Amar R. Deshpande, MD, David M. Pechman,
Matching methods for estimating causal effects Danilo Fusco Rome, October 15, 2012.
R. Papani, A. G. Duarte, Y-L. Lin, G. Sharma
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
Case 66 year old male with PMH of HTN, DM, ESRD on renal replacement TIW, stroke in 2011 with right side residual weakness, atrial fibrillation, currently.
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Background/Objective
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Results from the intermountain heart collaborative study
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Update on the Watchman Device CRT 2010 Washington, DC
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
The Intermountain heart collaborative study
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Patient populations by study group figure 10
Diagnostic characteristics and prognoses of primary-care patients referred for clinical exercise testing: a prospective observational study Nilsson G1,
HOPE: Heart Outcomes Prevention Evaluation study
The IDEAL Study Reference
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice.
No evidence that AF type significantly impacts stroke risk
Improved Outcomes in Patients with Non-ST-Elevation Myocardial Infarction during 20 Years are Related to Implementation of Evidence-based Treatments –
Siddharth Sheth, Abuzar Moradi Tuchayi, Roy E Smith
Prevalence and control of cardiovascular risk factors using a German sample – Findings from the STAAB Cohort Study Theresa Tiffe1,3, Götz Gelbrich1,2,
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Epidemiology of Atrial Fibrillation in Europe:
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
The Hypertension in the Very Elderly Trial (HYVET)
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
Quantitating the Dose of Physical Activity in Secondary Prevention: Relation of Exercise Intensity to Survival  Barry A. Franklin, PhD  Mayo Clinic Proceedings 
Impact of Platelet Reactivity Following Clopidogrel Administration
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease  Johannes F.E. Mann, Qi-Long.
Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.
Peter Gillgren ACST-2 , Sept 4:th, 2017.
Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus  James H. O'Keefe, MD, Mohammad Abuannadi,
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Procedural Characteristics
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Figure 8. Stroke prevention strategy in patients with AF
Figure 9.1.a Causes of death in ESRD patients,
Presentation transcript:

History Of Atrial Fibrillation In A First-Degree Relative And Risk Of Cardiovascular Events Daniele Pastori(1), Pasquale Pignatelli(1), Tommasa Vicario(1), Danilo Menichelli(1), Francesco Perticone(2), Angela Sciacqua(2), Francesco Violi(1) and the Atherosclerosis in Atrial Fibrillation (ATHERO-AF) Study Group* (1) I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome; (2) Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Italy Background Materials & Methods Results Table 1. Baseline characteristics of patients Variables Overall Familiarity for AF p value (n=1289) No (n=1030) Yes (n=259) Age (years) 73,2±9,1 73,7±8,9 71,1±9,6 <0.001 Women (%) 44,0 43,2 47,3 0,262 Arterial Hypertension (%) 87,8 87,5 89,1 0,523 Diabetes (%) 21,8 21,6 22,6 0,736 Heart failure (%) 15,6 15,4 16,5 0,699 Previous cerebrovascular events (%) 13,6 14,0 12,2 0,476 Previous cardiovascular events (%) 18,5 18,1 20,4 0,417 Prospective multicenter cohort study including 1309 anticoagulated AF patients. Familial AF was defined as the presence of known history of AF in a first-degree family member: parents, sibling, or children. AF patients were recruited from the Atherothrombosis Centre of I Clinica Medica of “Sapienza” University of Rome, from the Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Italy. Primary outcome was a composite of CVEs including fatal/non-fatal ischemic stroke and myocardial infarction (MI), arterial revascularization (both cardiac and peripheral) and cardiovascular (CV) death. Diagnosis of MI was made according to the definition proposed by the Joint ESC/ACCF/AHA/WHF Task Force. The occurrence of ischemic stroke was determined on clinical manifestations and confirmed by radiological findings. If a patient died within 4 weeks of MI or ischemic stroke, these events were recorded as fatal MI or ischemic stroke, respectively. Death was classified as CV unless an unequivocal non-CV cause of death was identified. CV death included sudden death; progressive congestive heart failure; procedure related death. Data on CV events were prospectively collected during follow-up, and only the first CV event was used for the analysis. Mean age was 73.2±9.1 years and 44% were women; 20 patients were excluded for missing informations about family history. Familial AF was present in 259 (20.1%) patients; in 14,3% of familial cases, more than 1 relative had a history of AF. Patients with familial AF had an earlier onset of AF compared to non-familial (Figure 1, p<0.001). Moreover, AF patients with multiple familial AF showed a further early onset of AF compared to those with single familial AF (60.7±12.3 vs. 66.2±10.1, respectively p=0.003). Baseline characteristics of patients included in the study are reported in Table 1. The presence of familial AF was associated with an increased rate of CVEs (n=117) at a median follow-up of 24 months (Log-rank test, p=0.024, Figure 2). Familial atrial fibrillation (AF) has been shown to be a risk factor for new-onset AF. The association between the presence of familial AF and cardiovascular events (CVEs) in a large cohort of elderly patients with AF has never been investigated. Objective To investigate the relationship between familial AF and CVEs in a prospective cohort of AF patients At Cox multivariable regression analysis, familial AF (HR 1.99 95%CI 1.32-3.02, p=0.001), male gender (HR 1.61 95%CI 1.09-2.37, p=0.017), age (HR 1.08, 95%CI 1.05-1.11,, p<0.001), previous stroke/TIA (HR 1.67 95%CI 1.08-2.59, p=0.022), previous myocardial infarction (HR 1.58, 95%CI 1.05-2.38, p=0.028), heart failure (HR 1.66, 95%CI 1.07-2.56, p=0.022), after adjustment for hypertension and diabetes. Figure 2. Conclusions Our study show a high prevalence of familial AF, which confers an increased risk for CVEs. These results claim for the need of recognizing patients with familial AF, as to plan appropriate and cost-effective prevention strategies. * ATHERO-AF Study Group Members: Mirella Saliola, Fabiana Albanese, Francesco Cribari, Francesco Del Sole, Alberto Paladino, Roberto Carnevale, Simona Bartimoccia, Cristina Nocella, Marta Novo Contact mail: daniele.pastori@uniroma1.it. Disclosures: none.